Swiss Nordic Bio Zurich 25 January 2022
| Reference number | |
| Coordinator | Mod4Sim pharma AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | December 2021 - January 2022 |
| Status | Completed |
Important results from the project
** Denna text är maskinöversatt ** Mod4Sim Pharma AB was started in 2019 and is active in drug development. The company uses AI and physics-based methods and has developed unique state-of-the-art software to calculate the interaction between drug molecules and protein targets. The purpose is to perform virtual screenings and to accelerate the identification of lead compounds.
Expected long term effects
** Denna text är maskinöversatt ** The Swiss Nordic Bio forum will allow us to connect with potential investors and present our company, and we are also applying for a pitch presentation. The forum will offer a fantastic opportunity for networking with other small and medium-sized companies from Sweden and Nordic countries in the life science area, with the idea of laying the groundwork for potential collaborative efforts in multidisciplinary project in drug development and molecular design.
Approach and implementation
** Denna text är maskinöversatt ** Dr Willem Jespers, Chief Scientific Officer and Dr Marc Willuhn, Business Development will participate in Swiss Nordic Bio in Zurich to present the company Mod4Sim Pharma and to seek contact with potential investors.